Pomegranate extract demonstrate a selective estrogen receptor modulator profile in human tumor cell lines and in vivo models of estrogen deprivation

Journal of Nutritional Biochemistry

Volumn 23, Issue 7, 2012, Pages 725-732

  Sreeja, Sreekumar ^a   Santhosh Kumar, Thankayyan R ^a   Lakshmi, Baddireddi S ^b   Sreeja, Sreeharshan ^a  

^a RAJIV GANDHI CENTRE FOR BIOTECHNOLOGY   (India)

^b ANNA UNIVERSITY   (India)

Author keywords

Breast cancer; Estrogen; Estrogen receptors; Pomegranate; Selective estrogen receptor modulator (SERM); Uterotrophic assay

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR; METHANOL; POMEGRANATE EXTRACT; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ANIMAL EXPERIMENT; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HEART PROTECTION; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; POMEGRANATE; UTERUS WEIGHT;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CELL LINE, TUMOR; CELL PROLIFERATION; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; FEMALE; FRUIT; GENES, REPORTER; HUMANS; MICE; PLANT EXTRACTS; PUNICACEAE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TRANSFECTION;

LYTHRACEAE; MUS;

EID: 84862331095     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2011.03.015     Document Type: Article

References (54)

1. Longtin R. The pomegranate: nature's power fruit?. J Natl Cancer Inst 2003, 95:346-348.
2. Gil M.I., Tomas-Barberan F.A., Hess-Pierce B., Holcroft D.M., Kader A.A. Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing. J Agric Food Chem 2000, 48:4581-4589.
3. Kim N.D., Mehta R., Yu W., Neeman I., Livney T., Amichay A., et al. Chemopreventive and adjuvant therapeutic potential of pomegranate (Punica granatum) for human breast cancer. Breast Cancer Res Treat 2002, 71:203-217.
4. Toi M., Bando H., Ramachandran C., Melnick S.J., Imai A., Fife R.S., et al. Preliminary studies on the anti-angiogenic potential of pomegranate fractions in vitro and in vivo. Angiogenesis 2003, 6:121-128.
5. Mehta R., Lansky E.P. Breast cancer chemopreventive properties of pomegranate (Punica granatum) fruit extracts in a mouse mammary organ culture. Eur J Cancer Prev 2004, 13:345-348.
6. Singh R.P., Chidambara Murthy K.N., Jayaprakasha G.K. Studies on the antioxidant activity of pomegranate (Punica granatum) peel and seed extracts using in vitro models. J Agric Food Chem 2002, 50:81-86.
7. Chidambara Murthy K.N., Jayaprakasha G.K., Singh R.P. Studies on antioxidant activity of pomegranate (Punica granatum) peel extract using in vivo models. J Agric Food Chem 2002, 50:4791-4795.
8. Stossi F., Barnett D.H., Frasor J., Komm B., Lyttle C.R. Katzenellenbo-Bogen, B.S. Transcriptional profiling of estrogen-regulated gene expression via estrogen receptor (ER) alpha or ER beta in human osteosarcoma cells: distinct and common target genes for these receptors. Endocrinology 2004, 145:3473-3486.
9. Deroo B.J., Korach K.S. Estrogen receptors and human disease. J Clin Invest 2006, 116:561-570.
10. Henderson B.E., Feigelson H.S. Hormonal carcinogenesis. Carcinogenesis 2000, 21:427-433.
11. Jensen E.V., Jacobson H.I., Walf A.A., Frye C.A. Estrogen action: a historic perspective on the implications of considering alternative approaches. Physiol Behav 2010, 99:151-162.
12. Shang Y., Brown M. Molecular determinants for the tissue specificity of SERMs. Science 2002, 295:2465-2468.
13. Yao K., Jordan V.C. Questions about tamoxifen and the future use of antiestrogens. Oncologist 1998, 3:104-110.
14. Fisher B., Dignam J., Bryant J., DeCillis A., Wickerham D.L., Wolmark N., et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996, 88:1529-1542.
15. Cortesi L., De Matteis E., Rashid I., Cirilli C., Proietto M., Rivasi F., et al. Distribution of second primary malignancies suggests a bidirectional effect between breast and endometrial cancer: a population-based study. Int J Gynecol Cancer 2009, 19:1358-1363.
16. Katzennenbogen B.S., Montano M.M., Ediger T.R., Sun J., Ekena K., Lazennec G., et al. Estrogen receptors: selective ligands, partners, and distinctive pharmacology. Recent Prog Horm Res 2000, 55:163-195.
17. Pettersson K., Gustafsson J.A. Role of estrogen receptor α in estrogen action. Annu Rev Physiol 2001, 63:165-192.
18. McDonnell D.P., Norris J.D. Connections and regulation of the human estrogen receptor. Science 2002, 296:1642-1644.
19. Klinge C.M. Estrogen receptor interaction with estrogen response elements. Nucleic acids research 2001, 29:2905-2919.
20. Kushner P.J., Agard D.A., Greene G.L., Scanlan T.S., Shiau A.K., Uht R.M., et al. Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol 2000, 74:311-317.
21. Safe S. Transcriptional activation of genes by 17 beta-estradiol through estrogen receptor-Sp1 interactions. Vitam Horm 2001, 62:231-252.
22. Hall J.M., Couse J.F., Korach K.S. The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem 2001, 276:36869-36872.
23. Shang Y., Hu X., DiRenzo J., Lazar M.A., Brown M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 2000, 103:843-852.
24. McKenna N.J., O'Malley B.W. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 2002, 108:465-474.
25. Osborne C.K., Zhao H., Fuqua S.A. Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol 2000, 18:3172-3186.
26. McCarthy T.L., Clough M.E., Gundberg C.M. Expression of an estrogen receptor agonist in differentiating osteoblast cultures. Proc Natl Acad Sci U S A 2008, 105:7022-7027.
27. Hewitt S.C., Harrell J.C., Korach K.S. Lessons in estrogen biology from knockout and transgenic animals. Annu Rev Physiol 2005, 67:285-308.
28. Cvoro A., Tzagarakis-Foster C., Tatomer D., Paruthiyil S., Fox M.S., Leitman D.C. Distinct roles of unliganded and liganded estrogen receptors in transcriptional repression. Mol Cell 2006, 21:555-564.
29. Canel J.P. Natural products isolation. Methods in Biotechnology 1998, 4:220-222.
30. Karumi Y., Onnyeyili P.A., Ogugbuaja V.O. Identification of active principles of M. balsamia (balsam apple) leaf extract. J Med Sci 2004, 4:179-182.
31. Chang C., Yang M., Wen H., Chern J. Estimation of total flavonoids content in propolis by two complementary colorimetric methods. J Food Drug Analysis 2002, 10:178-182.
32. Haridas V., Darnay B.G., Natarajan K., Heller R., Aggarwal B.B. Overexpression of the p80 TNF receptor leads to TNF-dependent apoptosis, nuclear factor-kappa B activation, and c-Jun kinase activation. J Immunol 1998, 160:3152-3162.
33. Clark J.H., Hardin J.W., McCormack S.A. Mechanism of action of estrogen agonists and antagonists. J Anim Sci 1979, 49(Suppl 2):46-65.
34. Sreeja S., Sreeja S. An in vitro study on antiproliferative and antiestrogenic effects of Boerhaavia diffusa L. extracts. J Ethnopharmacol 2009, 126(2):221-225.
35. Wanforth H.B., Flecknell P.A. Specific surgical operations. Experimental and surgical technique in the rat 1992, 203-312. Academic Press, New York. 2nd ed.
36. Petanceska S.S., Nagy V., Frail D., Gandy S. Ovariectomy and 17beta-estradiol modulate the levels of Alzheimer's amyloid beta peptides in brain. Exp Gerontol 2000, 35:1317-1325.
37. Carthew P., Edwards R.E., Nolan B.M., Tucker M.J., Smith L.L. Compartmentalized uterotrophic effects of tamoxifen, toremifene, and estradiol in the ovariectomized Wistar (Han) rat. Toxicol Sci 1999, 48:197-205.
38. Lamar A.S., Fonseca G., Fuentes J.L., Cozzi R., Cundari E., Mario F., et al. Assessment of the genotoxic risk of Punica granatum L. (Punicaceae) whole fruit extracts. J Ethnopharmacol 2008, 115:416-422.
39. Denizot F., Lang R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 1986, 89:271-277.
40. Kassi E., Papoutsi Z., Fokialakis N., Messari I., Mitakou S., Moutsatsou P. Greek plant extracts exhibit selective estrogen receptor modulator (SERM)-like properties. J Agric Food Chem 2004, 52:6956-6961.
41. Papoutsi Z., Kassi E., Fokialakis N., Mitakou S., Lambrinidis G., Mikros E., et al. Deoxybenzoins are novel potent selective estrogen receptor modulators. Steroids 2007, 72:693-704.
42. Papoutsi Z., Kassi E., Papaevangeliou D., Pratsinis H., Zoumpourlis V., Halabalaki M., et al. Plant 2-arylobenzofurans demonstrate a selective estrogen receptor modulator profile. Steroids 2004, 69:727-734.
43. Markey C.M., Michaelson C.L., Veson E.C., Sonnenschein C., Soto A.M. The mouse uterotrophic assay: a re-evaluation of its validity in assessing the estrogenicity of bisphenol A. Environ Health Perspect 2001, 109:55-60.
44. Makela S., Savolainen H., Aavik E., Myllarniemi M., Strauss L., Taskinen E., et al. Differentiation between vasculoprotective and uterotrophic effects of ligands with different binding affinities to estrogen receptors alpha and beta. Proc Natl Acad Sci U S A 1999, 96:7077-7082.
45. Clode S.A. Assessment of in vivo assays for endocrine disruption. Best Pract Res Clin Endocrinol Metab 2006, 20:35-43.
46. Pratt S.E., Pollak M.N. Estrogen and antiestrogen modulation of MCF-7 human breast cancer cell proliferation is associated with specific alterations in accumulation of insulin-like growth factor binding proteins in conditioned media. Cancer Res 1993, 53:5193-5198.
47. Brown A.M., Jeltsch J.M., Roberts M., Chambon P. Activation of pS2 gene transcription is a primary response to estrogen in the human breast cancer cell line MCF-7. Proc Natl Acad Sci U S A 1984, 81:6344-6348.
48. Yao Y., Zhou Q. A novel antiestrogen agent Shikonin inhibits estrogen-dependent gene transcription in human breast cancer cells. Breast Cancer Res Treat 2010, 121:233-240.
49. Johnston S.R., Saccani-Jotti G., Smith I.E., Salter J., Newby J., Coppen M., et al. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res 1995, 55:3331-3338.
50. Masiakowski P., Breathnach R., Bloch J., Gannon F., Krust A., Chambon P. Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acids Res 1982, 10:7895-7903.
51. Ismail S.M. Endometrial changes during tamoxifen treatment. Lancet 1998, 351:838.
52. Assikis V.J., Jordan V.C. Gynecologic effects of tamoxifen and the association with endometrial carcinoma. Int J Gynaecol Obstet 1995, 49:241-257.
53. Rutqvist L.E., Mattsson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1993, 85:1398-1406.
54. Walsh B.W., Kuller L.H., Wild R.A., Paul S., Farmer M., Lawrence J.B., et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998, 279:1445-1451.